Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Immune checkpoint inhibitors (ICIs) represent an appealing treatment for patients with advanced urothelial cancer (aUC) and a poor performance status (PS). However, the benefit of ICIs for patients with a poor PS remains unknown. It was hypothesized that a poor Eastern Cooperative Oncology Group (ECOG) PS (≥2 vs 0-1) would correlate with shorter overall survival (OS) in patients receiving ICIs.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Cancer

Title: Cancer

Publisher: Wiley

ISSN (Electronic): 1097-0142

ISSN (Print): 0008-543X

Publication date (Electronic): March 15 2020

Volume: 126

Issue: 6

Affiliations

[1 ] Division of Oncology, Department of Medicine, University of Washington, Seattle, Washington.

[2 ] Division of Hematology, Department of Medicine, University of Washington, Seattle, Washington.

[3 ] Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia.

[4 ] Department of Medicine, University of Utah, Salt Lake City, Utah.

[5 ] Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Autonomous University of Barcelona, Barcelona, Spain.

[6 ] Division of Hematology/Oncology, Department of Medicine, University of Virginia School of Medicine, Charlottesville, Virginia.

[7 ] Division of Hematology/Oncology, Department of Medicine, Case Comprehensive Cancer Center, Cleveland, Ohio.

[8 ] Department of Medical Oncology, Montefiore Medical Center, Bronx, New York.

[9 ] Department of Urology, Montefiore Medical Center, Bronx, New York.

[10 ] Section of Hematology Oncology, Department of Medicine, University of Oklahoma Stephenson Cancer Center, Oklahoma City, Oklahoma.

[11 ] Medical Oncology Department, Hospital del Mar Research Institute, Barcelona, Spain.

[12 ] Department of Surgery and Cancer, Imperial College London, London, United Kingdom.

[13 ] Division of Hematology/Oncology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.

[14 ] Division of Hematology/Oncology, Department of Medicine, Penn State Cancer Institute, Hershey, Pennsylvania.

[15 ] Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland.

[16 ] Marques de Valdecilla University Hospital, Instituto de Investigacion Sanitaria Valdecilla, Santander, Spain.

[17 ] Department of Medicine and Oncology, Tulane University, New Orleans, Louisiana.

[18 ] Department of Medicine, University of Iowa, Iowa City, Iowa.

[19 ] Department of Oncology and Nuclear Medicine, University Hospital Center, Sisters of Charity Zagreb School of Medicine, Zagreb, Croatia.

[20 ] College of Medicine, Drexel University, Philadelphia, Pennsylvania.

[21 ] Division of Oncology, Department of Medicine, University of Iowa, Iowa City, Iowa.

[22 ] Division of Oncology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.

[23 ] Genitourinary Oncology Program, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

[24 ] Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.

Article

Mid ID: NIHMS1062430

DOI: 10.1002/cncr.32645

PMC ID: 7050422

PubMed ID: 31829450

SO-VID: bb0af7cf-3bcb-410e-ba33-6805e800c226

History

Keywords: immunotherapy,urothelial carcinoma,bladder cancer,performance status,outcomes research

Data availability:

Keywords: immunotherapy, urothelial carcinoma, bladder cancer, performance status, outcomes research

Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors.

Read this article at

Abstract

Related collections

Cancer Immunotherapy

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Similar content 221

Cited by 39